GLP-3 Retatrutide: an evidence-first deep dive

Already know this material? Pass the checkpoint and this lesson counts as complete.

Test out checkpoint

Test out: GLP-3 Retatrutide: an evidence-first deep dive

Already know the material? Pass this checkpoint without opening the lesson first.

Get every question correct to pass.

1. Which ordering best represents increasing evidence maturity?

Peer-reviewed Phase 2 → pivotal Phase 3 → regulatory review/approved labelMarketing post → mechanism → approvalOnline vial → press release → animal studyApproval → Phase 2 → discovery

2. Why should TRIUMPH-2 results stay attached to its study population?

It studied adults with obesity or overweight and type 2 diabetesPopulation never mattersIt was an animal trialIt studied only healthy volunteers

3. TRIUMPH-3 improved several cardiovascular risk factors. What conclusion is still too strong?

Retatrutide is proven to reduce major cardiovascular eventsSeveral measured cardiovascular risk factors improvedWeight fell in the studied populationDedicated cardiovascular-outcome evidence remains a separate question

4. What did the peer-reviewed Phase 2 trial show about adverse events?

Gastrointestinal events were common and dose-related, with a dose-related heart-rate increaseThere were no adverse eventsOnly skin reactions occurredSafety was not measured

5. Which summary is most accurate?

GLP-3 Retatrutide has powerful human trial evidence but remains investigationalGLP-3 Retatrutide is already an approved commercial medicineGLP-3 Retatrutide has only animal evidencePhase 3 automatically means every online product is equivalent

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide